Mark Sutherland

1.2k total citations
39 papers, 943 citations indexed

About

Mark Sutherland is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Mark Sutherland has authored 39 papers receiving a total of 943 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 13 papers in Immunology and 8 papers in Oncology. Recurrent topics in Mark Sutherland's work include Toxin Mechanisms and Immunotoxins (12 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Cancer therapeutics and mechanisms (5 papers). Mark Sutherland is often cited by papers focused on Toxin Mechanisms and Immunotoxins (12 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Cancer therapeutics and mechanisms (5 papers). Mark Sutherland collaborates with scholars based in United Kingdom, Germany and United States. Mark Sutherland's co-authors include Hendrik Fuchs, Christopher Bachran, Iring Heisler, Diana Bachran, Steven D. Shnyder, Laurence H. Patterson, T Schewe, Matthias F. Melzig, R Tauber and Santosh Nigam and has published in prestigious journals such as PLoS ONE, Cancer Research and Analytical Biochemistry.

In The Last Decade

Mark Sutherland

38 papers receiving 915 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Sutherland United Kingdom 19 581 293 118 114 103 39 943
Molly M. He United States 15 575 1.0× 105 0.4× 85 0.7× 129 1.1× 32 0.3× 19 1.0k
Massimiliano Perduca Italy 19 685 1.2× 171 0.6× 42 0.4× 167 1.5× 71 0.7× 76 1.1k
Yuping Liu China 20 507 0.9× 151 0.5× 160 1.4× 149 1.3× 38 0.4× 55 1.1k
Margherita Eufemi Italy 23 820 1.4× 190 0.6× 38 0.3× 139 1.2× 121 1.2× 59 1.3k
Carlos R. Figueiredo Brazil 22 651 1.1× 370 1.3× 135 1.1× 249 2.2× 33 0.3× 58 1.5k
Kenzo Ohtsuki Japan 22 889 1.5× 141 0.5× 172 1.5× 103 0.9× 75 0.7× 97 1.4k
Jeong‐Heon Ko South Korea 20 1.1k 2.0× 225 0.8× 48 0.4× 153 1.3× 74 0.7× 41 1.6k
Yingzhuan Zhan China 18 487 0.8× 197 0.7× 83 0.7× 97 0.9× 28 0.3× 39 1.0k
Peter A. Jekel Netherlands 22 902 1.6× 135 0.5× 66 0.6× 100 0.9× 138 1.3× 42 1.3k
Shaukat H. Rangwala United States 11 566 1.0× 89 0.3× 87 0.7× 65 0.6× 52 0.5× 17 1.3k

Countries citing papers authored by Mark Sutherland

Since Specialization
Citations

This map shows the geographic impact of Mark Sutherland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Sutherland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Sutherland more than expected).

Fields of papers citing papers by Mark Sutherland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Sutherland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Sutherland. The network helps show where Mark Sutherland may publish in the future.

Co-authorship network of co-authors of Mark Sutherland

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Sutherland. A scholar is included among the top collaborators of Mark Sutherland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Sutherland. Mark Sutherland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sutherland, Mark, Andrew H. Gordon, Helen Philippou, et al.. (2023). Synthesis and Biological Evaluation of Cyclobutane-Based β3 Integrin Antagonists: A Novel Approach to Targeting Integrins for Cancer Therapy. Cancers. 15(16). 4023–4023. 2 indexed citations
2.
El‐Tanani, Mohamed, Angela Platt‐Higgins, Yin-Fai Lee, et al.. (2022). Matrix metalloproteinase 2 is a target of the RAN-GTP pathway and mediates migration, invasion and metastasis in human breast cancer. Life Sciences. 310. 121046–121046. 21 indexed citations
3.
Keys, Timothy G., et al.. (2017). Exploring and Exploiting Acceptor Preferences of the Human Polysialyltransferases as a Basis for an Inhibitor Screen. ChemBioChem. 18(13). 1332–1337. 6 indexed citations
4.
Al–Saraireh, Yousef, Mark Sutherland, Friedrich Freiberger, et al.. (2013). Pharmacological Inhibition of polysialyltransferase ST8SiaII Modulates Tumour Cell Migration. PLoS ONE. 8(8). e73366–e73366. 49 indexed citations
5.
Sutherland, Mark, Jason H. Gill, Paul M. Loadman, et al.. (2012). Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder. Molecular Cancer Therapeutics. 12(1). 27–37. 36 indexed citations
6.
Fuchs, Hendrik, Diana Bachran, Alexander Weng, et al.. (2009). Saponins as Tool for Improved Targeted Tumor Therapies. Current Drug Targets. 10(2). 140–151. 64 indexed citations
7.
Sutton, Chris W., Mark Sutherland, Steven D. Shnyder, & Laurence H. Patterson. (2009). Improved preparation and detection of cytochrome P450 isoforms using MS methods. PROTEOMICS. 10(2). 327–331. 18 indexed citations
8.
Bachran, Christopher, Horst Dürkop, Mark Sutherland, et al.. (2009). Inhibition of Tumor Growth by Targeted Toxins in Mice is Dramatically Improved by Saponinum Album in a Synergistic Way. Journal of Immunotherapy. 32(7). 713–725. 33 indexed citations
9.
Bachran, Christopher, et al.. (2008). Saponins in Tumor Therapy. Mini-Reviews in Medicinal Chemistry. 8(6). 575–584. 91 indexed citations
10.
Bachran, Christopher, Mark Sutherland, Diana Bachran, & Hendrik Fuchs. (2007). Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer. Recent Patents on Drug Delivery & Formulation. 1(2). 105–115. 3 indexed citations
11.
Fuchs, Hendrik, Christopher Bachran, Tongyu Li, et al.. (2006). A cleavable molecular adapter reduces side effects and concomitantly enhances efficacy in tumor treatment by targeted toxins in mice. Journal of Controlled Release. 117(3). 342–350. 34 indexed citations
12.
Heisler, Iring, et al.. (2005). Combined application of saponin and chimeric toxins drastically enhances the targeted cytotoxicity on tumor cells. Journal of Controlled Release. 106(1-2). 123–137. 55 indexed citations
13.
Bachran, Christopher, Iring Heisler, Hendrik Fuchs, & Mark Sutherland. (2005). Influence of protein transduction domains on target-specific chimeric proteins. Biochemical and Biophysical Research Communications. 337(2). 602–609. 9 indexed citations
14.
Heisler, Iring, et al.. (2002). A Colorimetric Assay for the Quantitation of Free Adenine Applied to Determine the Enzymatic Activity of Ribosome-Inactivating Proteins. Analytical Biochemistry. 302(1). 114–122. 89 indexed citations
15.
16.
Nigam, Santosh, G. Sravan Kumar, Mark Sutherland, et al.. (1999). Metabolic suppression of platelet-type 12-lipoxygenase in human uterine cervix with invasive carcinoma. International Journal of Cancer. 82(6). 827–831. 9 indexed citations
17.
Reynaud, Dénis, Peter Demin, Mark Sutherland, Santosh Nigam, & C.R. Pace-Asciak. (1999). Hepoxilin signaling in intact human neutrophils: biphasic elevation of intracellular calcium by unesterified hepoxilin A3. FEBS Letters. 446(2-3). 236–238. 24 indexed citations
18.
19.
Forhead, Alison J., et al.. (1996). Comparison of angiotensin II type 1 receptor blockade and angiotensin‐converting enzyme inhibition in pregnant sheep during late gestation. British Journal of Pharmacology. 119(2). 393–401. 6 indexed citations
20.
Sutherland, Mark, H. J. J. van Vuuren, & Martha M. Howe. (1994). Cloning, sequence and in vitro transcription/translation analysis of a 3.2-kb EcoRI-HindIII fragment of Leuconostoc oenos bacteriophage L10. Gene. 148(1). 125–129. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Molly M. He Breakdown of academic impact, for papers by Massimiliano Perduca Breakdown of academic impact, for papers by Yuping Liu Breakdown of academic impact, for papers by Margherita Eufemi Breakdown of academic impact, for papers by Carlos R. Figueiredo Breakdown of academic impact, for papers by Kenzo Ohtsuki Breakdown of academic impact, for papers by Jeong‐Heon Ko Breakdown of academic impact, for papers by Yingzhuan Zhan Breakdown of academic impact, for papers by Peter A. Jekel Breakdown of academic impact, for papers by Shaukat H. Rangwala
Rankless by CCL
2026